The uncertain role of unmodified mesenchymal stem cells in tumor progression: What master switch?

Stem Cell Research and Therapy

Volumn 4, Issue 2, 2013, Pages

  Zhang, Liyang ^a   Xiang, Juanjuan ^a   Li, Guiyuan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL HETEROGENEITY; CELL ISOLATION; CELL POPULATION; CHRONIC MYELOID LEUKEMIA; FIBROSARCOMA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOREGULATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR GROWTH; ANIMAL; CYTOLOGY; GRAFT VS HOST DISEASE; IMMUNOLOGY; IMMUNOMODULATION; MESENCHYMAL STROMA CELL; METASTASIS; NEOPLASM; PATHOLOGY;

ANIMALS; CARCINOGENESIS; CELL DIFFERENTIATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOMODULATION; MESENCHYMAL STROMAL CELLS; NEOPLASM METASTASIS; NEOPLASMS; T-LYMPHOCYTES;

EID: 84875293950     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt170     Document Type: Review

References (88)

1. Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine. Sun XY, Nong J, Qin K, Warnock GL, Dai LJ, World J Stem Cells 2011 3 96 103 10.4252/wjsc.v3.i11.96 22180830
2. Mesenchymal stem cells engineered for cancer therapy. Shah K, Adv Drug Deliv Rev 2011 64 739 748 21740940
3. Mesenchymal stem cell-mediated gene delivery of bone morphogenetic protein-2 in an articular fracture model. Zachos T, Diggs A, Weisbrode S, Bartlett J, Bertone A, Mol Ther 2007 15 1543 1550 10.1038/sj.mt.6300192 17519894 (Pubitemid 47099312)
4. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, Ljungman P, Lonnies H, Nava S, Ringden O, Leukemia 2007 21 1733 1738 10.1038/sj.leu.2404777 17541394 (Pubitemid 47086763)
5. Mesenchymal stem cells: biology and clinical potential in type 1 diabetes therapy. Liu M, Han ZC, J Cell Mol Med 2008 12 1155 1168 10.1111/j.1582-4934. 2008.00288.x 18298656
6. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. Zhang M, Mal N, Kiedrowski M, Chacko M, Askari AT, Popovic ZB, Koc ON, Penn MS, FASEB J 2007 21 3197 3207 10.1096/fj.06-6558com 17496162
7. Generation of functional neural artificial tissue from human umbilical cord blood stem cells. Jurga M, Lipkowski AW, Lukomska B, Buzanska L, Kurzepa K, Sobanski T, Habich A, Coecke S, Gajkowska B, Domanska-Janik K, Tissue Eng Part C Methods 2009 15 365 372 10.1089/ten.tec.2008.0485 19719393
8. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Nagaya N, Fujii T, Iwase T, Ohgushi H, Itoh T, Uematsu M, Yamagishi M, Mori H, Kangawa K, Kitamura S, Am J Physiol Heart Circ Physiol 2004 287 2670 2676 10.1152/ajpheart.01071.2003 15284059 (Pubitemid 39557139)
9. Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track-letter. Torsvik A, Rosland GV, Svendsen A, Molven A, Immervoll H, McCormack E, Lonning PE, Primon M, Sobala E, Tonn JC, Goldbrunner R, Schichor C, Mysliwietz J, Lah TT, Motaln H, Knappskog S, Bjerkvig R, Cancer Res 2010 70 6393 6396 10.1158/0008-5472.CAN-10-1305 20631079
10. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Otsu K, Das S, Houser SD, Quadri SK, Bhattacharya S, Bhattacharya J, Blood 2009 113 4197 4205 10.1182/blood-2008-09-176198 19036701
11. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC, Ye L, Zhang X, Cell Res 2008 18 500 507 10.1038/cr.2008.40 18364678 (Pubitemid 351498857)
12. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Qiao L, Xu ZL, Zhao TJ, Ye LH, Zhang XD, Cancer Lett 2008 269 67 77 10.1016/j.canlet.2008.04.032 18571836
13. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T, J Exp Med 2006 203 1235 1247 10.1084/jem.20051921 16636132
14. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Klopp AH, Gupta A, Spaeth E, Andreeff M, Marini F, Stem Cells 2011 29 11 19 10.1002/stem.559 21280155
15. Inhibition of lung cancer cell proliferation mediated by human mesenchymal stem cells. Li L, Tian H, Chen Z, Yue W, Li S, Li W, Acta Biochim Biophys Sin (Shanghai) 2011 43 143 148 10.1093/abbs/gmq118
16. Human umbilical cord Wharton's jelly stem cell (hWJSC) extracts inhibit cancer cell growth in vitro. Gauthaman K, Yee FC, Cheyyatraivendran S, Biswas A, Choolani M, Bongso A, J Cell Biochem 2012 113 2027 2039 10.1002/jcb.24073 22275115
17. Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models. Pisati F, Belicchi M, Acerbi F, Marchesi C, Giussani C, Gavina M, Javerzat S, Hagedorn M, Carrabba G, Lucini V, Gaini SM, Bresolin N, Bello L, Bikfalvi A, Torrente Y, Cancer Res 2007 67 3054 3063 10.1158/0008-5472.CAN-06-1384 17409412 (Pubitemid 46724842)
18. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montagna D, Maccario R, Villa R, Daidone MG, Zuffardi O, Locatelli F, Cancer Res 2007 67 9142 9149 10.1158/0008-5472.CAN-06-4690 17909019 (Pubitemid 47535900)
19. Cancer stem cells: impact, heterogeneity, and uncertainty. Magee JA, Piskounova E, Morrison SJ, Cancer Cell 2012 21 283 296 10.1016/j.ccr.2012.03.003 22439924
20. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Rosland GV, Svendsen A, Torsvik A, Sobala E, McCormack E, Immervoll H, Mysliwietz J, Tonn JC, Goldbrunner R, Lonning PE, Bjerkvig R, Schichor C, Cancer Res 2009 69 5331 5339 10.1158/0008-5472.CAN-08-4630 19509230
21. Spontaneous human adult stem cell transformation. Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A, Cancer Res 2005 65 3035 3039 15833829 (Pubitemid 40524580)
22. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Wang Y, Huso DL, Harrington J, Kellner J, Jeong DK, Turney J, McNiece IK, Cytotherapy 2005 7 509 519 10.1080/14653240500363216 16306013 (Pubitemid 43078081)
23. Polyploidization of murine mesenchymal cells is associated with suppression of the long non-coding RNA H19 and reduced tumorigenicity. Shoshani O, Massalha H, Shani N, Kagan S, Ravid O, Madar S, Trakhtenbrot L, Leshkowitz D, Rechavi G, Zipori D, Cancer Res 2012 72 6403 6413 10.1158/0008-5472.CAN-12-1155 23047867
24. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA, Nature 2007 449 557 563 10.1038/nature06188 17914389 (Pubitemid 47525152)
25. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F, PLoS One 2009 4 4992 10.1371/journal.pone.0004992 19352430
26. Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Li HJ, Reinhardt F, Herschman HR, Weinberg RA, Cancer Discov 2012 2 840 855 10.1158/2159-8290.CD-12-0101 22763855
27. Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Halpern JL, Kilbarger A, Lynch CC, Cancer Lett 2011 308 91 99 10.1016/j.canlet.2011.04.018 21601983
28. Mesenchymal cell interaction with ovarian cancer cells triggers prometastatic properties. Lis R, Touboul C, Raynaud CM, Malek JA, Suhre K, Mirshahi M, Rafii A, PLoS One 2012 7 38340 10.1371/journal.pone.0038340 22666502
29. Mesenchymal stem cells in mammary adipose tissue stimulate progression of breast cancer resembling the basal-type. Zhao M, Sachs PC, Wang X, Dumur CI, Idowu MO, Robila V, Francis MP, Ware J, Beckman M, Rizki A, Holt SE, Elmore LW, Cancer Biol Ther 2012 13 782 792 10.4161/cbt.20561 22669576
30. Origin of endothelial progenitors in human postnatal bone marrow. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM, J Clin Invest 2002 109 337 346 11827993 (Pubitemid 34141807)
31. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, Werner C, Stem Cells 2004 22 377 384 10.1634/stemcells.22-3-377 15153614 (Pubitemid 38736621)
32. Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with NRP-1. Dhar K, Dhar G, Majumder M, Haque I, Mehta S, Van Veldhuizen PJ, Banerjee SK, Banerjee S, Mol Cancer 2010 9 209 10.1186/1476-4598-9-209 20687910
33. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F, Leukemia 2007 21 304 310 10.1038/sj.leu.2404489 17170725 (Pubitemid 46158124)
34. Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T, Li L, Spaeth E, Xu W, Zhang X, Lewis MT, Reuben JM, Krishnamurthy S, Ferrari M, Gaspar R, Buchholz TA, Cristofanilli M, Marini F, Andreeff M, Woodward WA, PLoS One 2010 5 12180 10.1371/journal.pone.0012180 20808935
35. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton. Chanda D, Kumar S, Ponnazhagan S, J Cell Biochem 2010 111 249 257 10.1002/jcb.22701 20506559
36. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D, Nature 2005 438 820 827 10.1038/nature04186 16341007 (Pubitemid 41753060)
37. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, Jung Y, Dontu G, Taichman R, Wicha MS, Cancer Res 2011 71 614 624 10.1158/0008-5472.CAN-10-0538 21224357
38. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, Garcia-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, Lyden D, Nat Med 2012 18 883 891 10.1038/nm.2753 22635005
39. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Sceneay J, Chow MT, Chen A, Halse HM, Wong CS, Andrews DM, Sloan EK, Parker BS, Bowtell DD, Smyth MJ, Moller A, Cancer Res 2012 72 3906 3911 10.1158/0008-5472.CAN-11- 3873 22751463
40. Migratory neighbors and distant invaders: tumor-associated niche cells. Wels J, Kaplan RN, Rafii S, Lyden D, Genes Dev 2008 22 559 574 10.1101/gad.1636908 18316475 (Pubitemid 351342429)
41. Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. Paunescu V, Bojin FM, Tatu CA, Gavriliuc OI, Rosca A, Gruia AT, Tanasie G, Bunu C, Crisnic D, Gherghiceanu M, Tatu FR, Tatu CS, Vermesan S, J Cell Mol Med 2011 15 635 646 10.1111/j.1582-4934.2010.01044.x 20184663
42. Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression. Dawson MR, Chae SS, Jain RK, Duda DG, Am J Cancer Res 2011 1 144 154 21822499
43. Tumor-conditioned mesenchymal stem cells display hematopoietic differentiation and diminished influx of ca(2+). Zhang L, Tang A, Zhou Y, Tang J, Luo Z, Jiang C, Li X, Xiang J, Li G, Stem Cells Dev 2012 21 1418 1428 10.1089/scd.2011.0319 21905919
44. A sub-population of high proliferative potential-quiescent human mesenchymal stem cells is under the reversible control of interferon alpha/beta. Peiffer I, Eid P, Barbet R, Li ML, Oostendorp RA, Haydont V, Monier MN, Milon L, Fortunel N, Charbord P, Tovey M, Hatzfeld J, Hatzfeld A, Leukemia 2007 21 714 724 10.1038/sj.leu.2404589 17375123 (Pubitemid 46444555)
45. Phenotype and chondrogenic differentiation of mesenchymal cells from adipose tissue of different species. Martinez-Lorenzo MJ, Royo-Canas M, Alegre-Aguaron E, Desportes P, Castiella T, Garcia-Alvarez F, Larrad L, J Orthop Res 2009 27 1499 1507 10.1002/jor.20898 19408284
46. Differentiation of synovial CD-105(+) human mesenchymal stem cells into chondrocyte-like cells through spheroid formation. Arufe MC, De la Fuente A, Fuentes-Boquete I, De Toro FJ, Blanco FJ, J Cell Biochem 2009 108 145 155 10.1002/jcb.22238 19544399
47. A subpopulation of mesenchymal stromal cells with high osteogenic potential. Liu H, Toh WS, Lu K, MacAry PA, Kemeny DM, Cao T, J Cell Mol Med 2009 13 2436 2447 10.1111/j.1582-4934.2009.00793.x 19508389
48. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Tondreau T, Meuleman N, Delforge A, Dejeneffe M, Leroy R, Massy M, Mortier C, Bron D, Lagneaux L, Stem Cells 2005 23 1105 1112 10.1634/stemcells.2004-0330 15955825 (Pubitemid 41377726)
49. Mesenchymal stromal cells can be derived from bone marrow CD133+ cells: implications for therapy. Pozzobon M, Piccoli M, Ditadi A, Bollini S, Destro R, Andre-Schmutz I, Masiero L, Lenzini E, Zanesco L, Petrelli L, Cavazzana-Calvo M, Gazzola MV, De Coppi P, Stem Cells Dev 2009 18 497 510 10.1089/scd.2008.0003 18598159
50. The subpopulation of mesenchymal stem cells that differentiate toward cardiomyocytes is cardiac progenitor cells. Wei F, Wang T, Liu J, Du Y, Ma A, Exp Cell Res 2011 317 2661 2670 10.1016/j.yexcr.2011.08.011 21878326
51. A specific subpopulation of mesenchymal stromal cell carriers overrides melanoma resistance to an oncolytic adenovirus. Bolontrade MF, Sganga L, Piaggio E, Viale DL, Sorrentino MA, Robinson A, Sevlever G, Garcia MG, Mazzolini G, Podhajcer OL, Stem Cells Dev 2012 21 2689 2702 10.1089/scd.2011.0643 22462538
52. Mesenchymal stem cells and their potential as cardiac therapeutics. Pittenger MF, Martin BJ, Circ Res 2004 95 9 20 10.1161/01.RES.0000135902.99383. 6f 15242981 (Pubitemid 38931831)
53. Comparison of different methods for the isolation of mesenchymal stem cells from human umbilical cord Wharton's jelly. Salehinejad P, Alitheen NB, Ali AM, Omar AR, Mohit M, Janzamin E, Samani FS, Torshizi Z, Nematollahi-Mahani SN, In Vitro Cell Dev Biol Anim 2012 48 75 83 10.1007/s11626-011-9480-x 22274909
54. Differences in surface marker expression and chondrogenic potential among various tissue-derived mesenchymal cells from elderly patients with osteoarthritis. Alegre-Aguarón E, Cells Tissues Organs 2012 196 231 240 22947769
55. A novel serum-free medium for the expansion of human mesenchymal stem cells. Chase LG, Lakshmipathy U, Solchaga LA, Rao MS, Vemuri MC, Stem Cell Res Ther 2010 1 8 10.1186/scrt8 20504289
56. Effects of high glucose on mesenchymal stem cell proliferation and differentiation. Li YM, Schilling T, Benisch P, Zeck S, Meissner-Weigl J, Schneider D, Limbert C, Seufert J, Kassem M, Schutze N, Jakob F, Ebert R, Biochem Biophys Res Commun 2007 363 209 215 10.1016/j.bbrc.2007.08.161 17868648 (Pubitemid 47430115)
57. CD45-CD14 +CD34 + murine bone marrow low-adherent mesenchymal primitive cells preserve multilineage differentiation potential in long-term in vitro culture. Szade K, Zuba-Surma E, Rutkowski AJ, Jozkowicz A, Dulak J, Mol Cells 2011 31 497 507 10.1007/s10059-011-2176-y 21533906
58. Perivascular human endometrial mesenchymal stem cells express pathways relevant to self-renewal, lineage specification, and functional phenotype. Spitzer TL, Rojas A, Zelenko Z, Aghajanova L, Erikson DW, Barragan F, Meyer M, Tamaresis JS, Hamilton AE, Irwin JC, Giudice LC, Biol Reprod 2012 86 58 10.1095/biolreprod.111.095885 22075475
59. Immunological properties of mesenchymal stem cells and clinical implications. Patel SA, Sherman L, Munoz J, Rameshwar P, Arch Immunol Ther Exp (Warsz) 2008 56 1 8
60. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Prevosto C, Zancolli M, Canevali P, Zocchi MR, Poggi A, Haematologica 2007 92 881 888 10.3324/haematol.11240 17606437 (Pubitemid 350144234)
61. Exploring the role of soluble factors associated with immune regulatory properties of mesenchymal stem cells. Bassi EJ, de Almeida DC, Moraes-Vieira PM, Camara NO, Stem Cell Rev 2012 8 329 342 10.1007/s12015-011-9311-1 21881832
62. Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants. Lin CS, Lin G, Lue TF, Stem Cells Dev 2012 21 2770 2778 10.1089/scd.2012.0176 22621212
63. Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. Xiang J, Tang J, Song C, Yang Z, Hirst DG, Zheng QJ, Li G, Cytotherapy 2009 11 516 526 10.1080/14653240902960429 19562576
64. Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis. Hao L, Sun H, Wang J, Wang T, Wang M, Zou Z, Int J Hematol 2011 95 34 46 22183780
65. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Chan JL, Tang KC, Patel AP, Bonilla LM, Pierobon N, Ponzio NM, Rameshwar P, Blood 2006 107 4817 4824 10.1182/blood-2006-01-0057 16493000 (Pubitemid 43882633)
66. Chondrogenic differentiation alters the immunosuppressive property of bone marrow-derived mesenchymal stem cells, and the effect is partially due to the upregulated expression of B7 molecules. Chen X, McClurg A, Zhou GQ, McCaigue M, Armstrong MA, Li G, Stem Cells 2007 25 364 370 10.1634/stemcells.2006-0268 17068184 (Pubitemid 46232790)
67. Hematopoiesis capacity, immunomodulatory effect and ex vivo expansion potential of mesenchymal stem cells are not impaired by cryopreservation. Zhao ZG, Li WM, Chen ZC, You Y, Zou P, Cancer Invest 2008 26 391 400 10.1080/07357900701788049 18443960 (Pubitemid 351601399)
68. The research on the immunomodulatory defect of mesenchymal stem cell from chronic myeloid leukemia patients. Xishan Z, Guangyu A, Yuguang S, Hongmei Z, J Exp Clin Cancer Res 2011 30 47 10.1186/1756-9966-30-47 21535879
69. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A, Dessoly J, Sciaini AK, Benbunan M, Chomienne C, Fermand JP, Marolleau JP, Larghero J, Leukemia 2007 21 158 163 10.1038/sj.leu.2404466 17096013 (Pubitemid 44921847)
70. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Perez-Simon JA, Tabera S, Sarasquete ME, Diez-Campelo M, Canchado J, Sanchez-Abarca LI, Blanco B, Alberca I, Herrero-Sanchez C, Canizo C, San Miguel JF, Cytotherapy 2009 11 698 705 10.3109/14653240903051558 19878056
71. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Djouad F, Fritz V, Apparailly F, Louis-Plence P, Bony C, Sany J, Jorgensen C, Noel D, Arthritis Rheum 2005 52 1595 1603 10.1002/art.21012 15880818 (Pubitemid 40663952)
72. Subpopulation composition and activation of T lymphocytes during coculturing with mesenchymal stromal cells in medium with different O(2) content. Buravkova LB, Grigorieva OG, Andreeva ER, Andrianova IV, Rylova YV, Bull Exp Biol Med 2011 151 344 346 10.1007/s10517-011-1326-8 22451883
73. Selected Stro-1-enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation. Nasef A, Zhang YZ, Mazurier C, Bouchet S, Bensidhoum M, Francois S, Gorin NC, Lopez M, Thierry D, Fouillard L, Chapel A, Int J Lab Hematol 2009 31 9 19 10.1111/j.1751-553X.2007.00997.x 19143868
74. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Francois M, Romieu-Mourez R, Stock-Martineau S, Boivin MN, Bramson JL, Galipeau J, Blood 2009 114 2632 2638 10.1182/blood-2009-02-207795 19654411
75. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Remberger M, Kumlien G, Aschan J, Barkholt L, Hentschke P, Ljungman P, Mattsson J, Svennilson J, Ringden O, Biol Blood Marrow Transplant 2002 8 674 682 10.1053/bbmt.2002.v8. abbmt080674 12523580 (Pubitemid 36097807)
76. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, Woolfrey AE, Chauncey TR, Flowers ME, Mielcarek M, Maloney DG, Storb R, J Clin Oncol 2005 23 1993 2003 10.1200/JCO.2005.08.136 15774790 (Pubitemid 46211379)
77. Murine retroviruses activate B cells via interaction with toll-like receptor 4. Rassa JC, Meyers JL, Zhang Y, Kudaravalli R, Ross SR, Proc Natl Acad Sci USA 2002 99 2281 2286 10.1073/pnas.042355399 11854525 (Pubitemid 34169052)
78. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, Deans RJ, McIntosh KR, J Biomed Sci 2005 12 47 57 10.1007/s11373-004-8183-7 15864738 (Pubitemid 40576763)
79. Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo. Radoja S, Rao TD, Hillman D, Frey AB, J Immunol 2000 164 2619 2628 10679101 (Pubitemid 30115493)
80. T-cell functions in nude mice: proliferation of spleen cells from athymic mice in the one-way xenogeneic mixed leucocyte reaction. Hammarstrom L, Smith CI, Scand J Immunol 1980 12 213 221 10.1111/j.1365-3083.1980.tb00061.x 6451025 (Pubitemid 10049022)
81. Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells. Petrini I, Pacini S, Petrini M, Fazzi R, Trombi L, Galimberti S, Eur J Clin Invest 2009 39 813 818 10.1111/j.1365-2362.2009.02171.x 19522834
82. Fractalkine mediates natural killer-dependent antitumor responses in vivo. Lavergne E, Combadiere B, Bonduelle O, Iga M, Gao JL, Maho M, Boissonnas A, Murphy PM, Debre P, Combadiere C, Cancer Res 2003 63 7468 7474 14612547 (Pubitemid 37413490)
83. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, Watanabe K, Niki T, Katoh S, Miyake M, Nagahata S, Hirabayashi J, Kuchroo VK, Yamauchi A, Hirashima M, J Immunol 2008 181 7660 7669 19017954
84. [Bone Marrow-derived Mesenchymal Stem Cells Regulate the Proliferation and Activity of Natural Killer Cells]. Wang HF, Shi YJ, Ren HY, Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012 20 438 442 22541115
85. Liver injury due to sequential activation of natural killer cells and natural killer T cells by carrageenan. Abe T, Kawamura H, Kawabe S, Watanabe H, Gejyo F, Abo T, J Hepatol 2002 36 614 623 10.1016/S0168-8278(02)00022-3 11983444 (Pubitemid 34499398)
86. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. Carson WE, Yu H, Dierksheide J, Pfeffer K, Bouchard P, Clark R, Durbin J, Baldwin AS, Peschon J, Johnson PR, Ku G, Baumann H, Caligiuri MA, J Immunol 1999 162 4943 4951 10202041 (Pubitemid 29314901)
87. Induction of NKG2D ligands by gamma radiation and tumor necrosis factor-alpha may participate in the tissue damage during acute graft-versus-host disease. Gannage M, Buzyn A, Bogiatzi SI, Lambert M, Soumelis V, Dal Cortivo L, Cavazzana-Calvo M, Brousse N, Caillat-Zucman S, Transplantation 2008 85 911 915 10.1097/TP.0b013e31816691ef 18360276 (Pubitemid 351440760)
88. Immunotherapeutic approaches to improve graft-versus-tumor effect and reduce graft-versus-host disease. Tsirigotis P, Or R, Resnick IB, Shapira MY, Immunotherapy 2012 4 407 424 10.2217/imt.12.14 22512635